Insider Trading Alert - JAZZ, GDOT And MDSO Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, April 10, 2014, 60 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1,413.00 to $30,206,707.91.

Highlighted Stocks Traded by Insiders:

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Cozadd Bruce C who is Chairman and CEO at Jazz Pharmaceuticals sold 5,000 shares at $123.18 on April 10, 2014. Following this transaction, the Chairman and CEO owned 611,810 shares meaning that the stake was reduced by 0.81% with the 5,000-share transaction.

Keegan Fintan who is EVP, Technical Operations at Jazz Pharmaceuticals sold 750 shares at $130.00 on April 10, 2014. Following this transaction, the EVP, Technical Operations owned 38,522 shares meaning that the stake was reduced by 1.91% with the 750-share transaction.

The shares most recently traded at $127.15, down $2.85, or 2.24% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 888
  • 12-Week # shares sold: 552,888
  • 24-Week # shares sold: 560,888

The average volume for Jazz Pharmaceuticals has been 1.3 million shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $8.0 billion and is part of the health care sector and drugs industry. Shares are up 2.41% year-to-date as of the close of trading on Thursday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a P/E ratio of 43.9. Currently there are 8 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Green Dot (GDOT) - FREE Research Report

Greenleaf Timothy R who is Director at Green Dot sold 50,000 shares at $20.11 on April 10, 2014. Following this transaction, the Director owned 269,954 shares meaning that the stake was reduced by 15.63% with the 50,000-share transaction.

The shares most recently traded at $19.54, down $0.57, or 2.92% since the insider transaction. Historical insider transactions for Green Dot go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 10,000
  • 24-Week # shares sold: 10,000

The average volume for Green Dot has been 660,300 shares per day over the past 30 days. Green Dot has a market cap of $765.8 million and is part of the services sector and diversified services industry. Shares are down 22.07% year-to-date as of the close of trading on Thursday.

Green Dot Corporation, together with its subsidiaries, operates as a technology-centric, pro-consumer bank holding company that provides personal banking for the masses. The company has a P/E ratio of 27.5. Currently there are 3 analysts that rate Green Dot a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GDOT - FREE

TheStreet Quant Ratings rates Green Dot as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Green Dot Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Medidata Solutions (MDSO) - FREE Research Report

De Vries Glen Michael who is President at Medidata Solutions sold 20,000 shares at $47.71 on April 10, 2014. Following this transaction, the President owned 1.1 million shares meaning that the stake was reduced by 1.82% with the 20,000-share transaction.

The shares most recently traded at $48.31, up $0.60, or 1.23% since the insider transaction. Historical insider transactions for Medidata Solutions go as follows:

  • 4-Week # shares sold: 20,000
  • 12-Week # shares sold: 145,347
  • 24-Week # shares sold: 365,679

The average volume for Medidata Solutions has been 699,600 shares per day over the past 30 days. Medidata Solutions has a market cap of $2.7 billion and is part of the technology sector and computer software & services industry. Shares are down 20.25% year-to-date as of the close of trading on Thursday.

Medidata Solutions, Inc. provides cloud-based clinical development solutions for life sciences in the United States and internationally. The company has a P/E ratio of 211.2. Currently there are 6 analysts that rate Medidata Solutions a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDSO - FREE

TheStreet Quant Ratings rates Medidata Solutions as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk. Get the full Medidata Solutions Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers